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SUMMARY
We describe the development of the HIV epidemic in Karonga District, Malawi over 22 years using
data from population surveys and community samples. These data are used to estimate the trend
in HIV prevalence, incidence and need for antiretroviral treatment (ART) using a simple
mathematical model. HIV prevalence rose quickly in the late 1980s and early 1990s, stabilizing
at around 12% in the mid-1990s. Estimated annual HIV incidence rose quickly, peaking in the
early 1990s at 2.2% among males and 3.1% among females, and then levelled oﬀ at 1.3% among
males and 1.1% among females by the late 1990s. Assuming a 2-year eligibility period, both our
model and the UNAIDS models predicted 2.1% of adults were in need of ART in 2005. This
prediction was sensitive to the assumed eligibility period, ranging from 1.6% to 2.6% if the
eligibility period was instead assumed to be 1.5 or 2.5 years, respectively.
INTRODUCTION
After a period of rapid increase, HIV prevalence
has stabilized in several countries in recent years. In
Malawi this has been seen in national estimates [1]
and in epidemiological studies [2]. Trends in HIV
incidence are less well known but are crucial for
planning and evaluating interventions. Past as well
as current incidence determines the proportion of
individuals living with HIV who have been infected
for diﬀerent lengths of time, and hence the likely
proportion of HIV-infected individuals who would
beneﬁt from the introduction of antiretroviral therapy
(ART).
In Karonga District, Malawi, information on
HIV prevalence has been available since 1981, based
on population surveys, community samples and
antenatal clinic (ANC) surveillance [2, 3]. This study
demonstrates how these data can be used to estimate
age- and sex-speciﬁc HIV prevalence and incidence
trends from the ﬁrst introduction of HIV until 2004,
and to predict the initial need for antiretrovirals.
ART roll-out, under the Malawi national scheme was
started in 2004 and the ﬁrst ART clinic in Karonga
District opened in mid-2005.
METHODS
Data
Karonga District is in the north of Malawi. It is
a rural area with a current population of around
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238 000. The data described here were collected
within the context of the Karonga Prevention Study,
a long-term epidemiological research programme,
whose methods have been described in detail [2, 3].
House-to-house total population surveys were con-
ducted in 1980–1984 and 1986–1989 [4]. HIV preva-
lence was measured in all individuals living in two
areas of the district during these surveys using dried
blood spots collected on ﬁlter papers [3]. Case-control
studies of HIV as a risk factor for tuberculosis and
leprosy were conducted between 1988 and 1993 [5, 6],
and between 1998 and 2004 [7]. The controls at
each period were randomly selected from the whole
district population but with an age, sex and area dis-
tribution similar to that of tuberculosis and leprosy
cases. Controls were interviewed and blood was
taken for HIV testing, after counselling and if consent
was given. ANC sentinel surveillance for HIV started
in four clinics in the district in 1999. Women attending
for their ﬁrst visit for that pregnancy were interviewed
and venous blood was taken for syphilis testing and
subsequently anonymized, unlinked from personal
identiﬁers and tested for HIV. Each year, data col-
lection continued in each clinic until 250 women had
been seen.
For dried blood spot specimens collected in
1981–1984 and 1986–1989 HIV testing used a par-
ticle agglutination assay for anti-HIV-1 (Edgware
modiﬁcation of the Serodia; Mast Diagnostics
Ltd, Bootle, Merseyside, UK), with conﬁrmation
of positive samples using an ELISA (Vironostika
HIV kit, Organon Teknika, Cambridge, UK) and a
particle agglutination assay (Serodia; Fujirebio
Inc., Tokyo, Japan). In 1988–1993, initial testing on
the venous blood samples used an enzyme-linked
immunosorbent assay (ELISA Organon Vironostika,
Durham, NC, USA) and particle agglutination test
(Edgware modiﬁcation of the Serodia). Positives
were conﬁrmed using a further ELISA, Wellcozyme
(Wellcome Diagnostics, Dartford, UK) or Behring
Enzygnost (Marburg, Germany) and particle ag-
glutination assay (Fujirebio). From 1998, the ﬁrst
two tests were conducted as before, and samples
giving discrepant results were repeated in duplicate
using the same two tests. Repeated discrepancies
were analysed by Western blot. HIV testing in
each study and of the archived samples was ap-
proved by the National Health Sciences Research
Committee of Malawi and the Ethics Committee
of the London School of Hygiene and Tropical
Medicine.
Direct standardization was used to estimate
HIV prevalence for the whole district adjusted by
age and area of residence, separately for men and
women. District data from the 1998 national census
were used for the age distribution. The district was
divided into six areas and the 1986–1989 survey
data were used for the percentage of the popu-
lation in each [2]. The ANCs were held in four
of these areas but women resident in all six areas
attended; area of residence was used for the stan-
dardization.
HIV prevalence data from 1981–1984 and 1987–
1989 were available from two of the areas. The HIV
prevalence for the whole district in 1981–1984 and
1987–1989 was estimated by assuming that the
relative prevalence of HIV in these areas and in
the whole district was the same as that among the
community controls in 1988–1990.
Mathematical model
We extended methods that have been used pre-
viously to estimate HIV incidence during the growth
phase of the HIV epidemic [8, 9]. These previous
models have assumed that the prevalence of HIV
was increasing exponentially and that the median
survival time of HIV positive individuals, modelled
as a Weibull distribution, was either 7 years, irres-
pective of the age at infection [8], or decreased with
the age at infection but was identical to that
measured in developed counties (overall median=10
and 11 years for males and females respectively [9]).
Here, we estimated the age-, sex- and time-speciﬁc
incidence of HIV in Karonga allowing for (i) a
levelling oﬀ or a decrease in the HIV incidence,
and (ii) age-dependent survival among HIV-positive
individuals measured in developing countries, as
described below.
The HIV incidence for individuals of age a at
time t was given by the expression i(a, t)=r(a)f(t)
where r(a) describes the dependence of the HIV
incidence on age a of individuals at a given time t,
and f(t) describes the dependence of the HIV
incidence on time t for individuals of age a. r(a) was
assumed to follow a Weibull distribution, with
the youngest and oldest age at HIV infection being
13 and 75 years respectively. Two alternative as-
sumptions for the change in the HIV incidence over
time f(t) were explored. In the ﬁrst, simpler model 1,
the HIV incidence was permitted to rise and level oﬀ
over time, but not fall. In the second model 2, the
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HIV incidence was permitted to rise and then either
level oﬀ or fall over time. In these two models f(t)
was described using a single or double-logistic func-
tion respectively:
Model 1: No decline in HIV incidence
f(t)=
cea(txt0)
1+ea(txt0)
:
Model 2: Decline in HIV incidence permitted
f(t)=
ea(txt0)
1+ea(txt0)
c+
bexa(txt0)
1+exa(txt0)
 
,
where c is the annual incidence when the epidemic
has levelled oﬀ (% per year), t0 determines the timing
of the epidemic (year), a determines the rate of
increase in the incidence during the growth phase of
the epidemic (% per year), and b determines the peak
incidence (% per year). The parameters deﬁning
models 1 and 2, together with those of the Weibull
distributions deﬁning the change in the HIV incidence
with age were estimated simultaneously by maximum-
likelihood methods for males and females separately
(see below).
In line with Gouws et al. [9] we assumed age-speciﬁc
survival by time since infection followed a Weibull
distribution. Gouws and colleagues ﬁtted Weibull
distributions to age-speciﬁc survival data measured in
Europe, North America and Australia [10]. Recent
data support a shorter time from HIV infection to
death in the developing world [11, 12] than in the
developed world, and therefore we proportionally
adjusted the age-speciﬁc survival to model a median
survival time of 9.8 years among the 25–34 years age
group (compared to 10.9 years among the same
age group in the CASCADE data [10]). The median
survival times among individuals infected between
5–14, 15–24, 25–34, 35–44, 45–54, 55–64 and o65
years were 12.5, 11.1, 9.8, 8.3, 7.1, 5.8 and 3.7 years
respectively.
The HIV incidence over time and by age was
estimated by ﬁtting expressions for the age- and
time-speciﬁcHIV prevalence as given inWilliams et al.
[8], taking into account age and time-dependent
HIV incidence as described above, to all the available
age-speciﬁc and overall age- and area-standardized
HIV prevalence data, using maximum-likelihood
methods [13, 14], for males and females and
for models 1 and 2 separately. Goodness-of-ﬁt was
assessed by calculating the deviance for males and
females and for models 1 and 2 separately, using the
expression:
2
X
a
X
t
S(a, t) ln [1xp^(a, t)]
+[N(a, t)xS(a, t)] ln [p^(a, t)]xS(a, t) ln [1xp(a, t)]
x[N(a, t)xS(a, t)] ln [ p(a, t)],
where S(a, t) is the observed number of individuals of
age a at time t who are not infected, N(a, t) is the
observed number of individuals of age a at time t who
were tested for HIV and p(a, t) is the model prediction
of the proportion positive and p^(a, t) is the observed
proportion positive.
The models calculate the proportion of the
population infected by HIV and the time since
infection, by age [8]. Because the survival by age at
infection is known, the time until death can also be
calculated. By assuming that the limited ART roll-out
in Karonga District to date has had little impact on
HIV/AIDS mortality, and by assuming a period of
eligibility for ART before death, the model was
then used to predict the proportion and number of
adults in Karonga District that were in need of
ART in 2005, by age and sex. The current estimates
made by UNAIDS assume that all those within 2
years of death from HIV/AIDS are eligible for ART,
regardless of the age of infection [15] based on a
literature review by Schneider et al. [16]. To allow
comparison between our estimates and those made
by UNAIDS we make the same assumption in our
default scenario. However, the data supporting this
assumption are equivocal [15, 16] and, therefore,
we also present estimates that (a) assume that all
that those within 1.5 or 2.5 years of death from
HIV/AIDS are eligible for ART, regardless of age
of infection, and (b) assume that the eligible period
decreases with increasing age at infection in line
with the data on survival. In the latter scenario
individuals aged 15–24, 25–34, 35–54, ando55 years
at infection, were assumed to be eligible for ART if
they were within 2.5, 2.0, 1.5 and 1.0 years of death
respectively.
The results were compared with those from the
combined UNAIDS EPP [17] and Spectrum [18]
models. These use overall estimates of adult preva-
lence by year, usually from ANC data. We ran these
standard models using our estimates of prevalence
among 15- to 44-year-old males and females separ-
ately to assess the reliability of the output of these
models for other settings.
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RESULTS
Observed HIV prevalence
The top two panels in Figure 1 show the age-
and area-standardized estimates of HIV prevalence
among males and females aged o15 years. HIV
prevalence rose quickly in the late 1980s and early
1990s. Since the early 1990s, the prevalence has been
relatively stable at around 12%.
Age- and area-standardized HIV prevalence among
women aged 15–44 years attending ANCs was also
stable from 1999–2002, around 10% (not shown).
Overall HIV prevalence among ANC women was
lower than among community controls of the same
age. Adjusting for parity [19], and assuming 21.5%
of women were childless [20], we estimated that the
mean HIV prevalence in women aged 15–44 years in
the community between 1999 and 2002, was 15.0%.
This was consistent with estimates from women in
the community of the same age [1998–2001: 14.2%
(95% CI 10.1–18.2) ; 2002–2004: 13.0% (95% CI
5.4–20.6)].
Observed and estimated overall HIV prevalence
The top two panels in Figure 1 also show the
HIV prevalence trend among adults in the com-
munity predicted by the two models. Both models
ﬁtted the HIV prevalence well before 1990 and
in 2000. Model 2, in which HIV incidence was
permitted to fall from its peak, provided a slightly
better ﬁt to both the male and female HIV preva-
lence data, especially for females in 1992 and 2003
(Fig. 1).
Estimated overall HIV incidence
The bottom two panels in Figure 1 show the estimated
trend in annual HIV incidence among males and
females in the community aged o15 years. Both
models predicted that HIV incidence rose quickly
in the late 1980s. Model 1, in which HIV incidence
was not permitted to decline, predicted that the
annual HIV incidence had levelled oﬀ by the mid-
1990s, at 1.6% among males and 1.8% among
females. Model 2, in which HIV incidence decline
was permitted, predicted that the annual HIV inci-
dence peaked in the early 1990s at 2.2% among males
and 3.1% among females, and then levelled oﬀ at
1.3% among males and 1.1% among females by the
late 1990s.
Observed and estimated age-speciﬁc HIV prevalence
Both models provided a very good ﬁt of HIV
prevalence by age, with most model estimates
lying within the 95%CIs associated with the observed
data (Fig. 2). The exceptions were: among males
in 1987–1989, both models overestimated the HIV
prevalence among the 15–24 years age group, and
underestimated the HIV prevalence among the 25–34
years age group; in 1988–1990 the models over-
estimated HIV prevalence among females aged 45–54
years ; and in 2002–2004 the models overestimated
HIV prevalence among males aged 25–34 years.
Model 2 in which HIV incidence was permitted
to decrease, led to a slightly higher projected HIV
prevalence in all age groups between 1991 and 1993
and slightly lower HIV prevalence in all age groups
between 2002 and 2004 than model 1, but otherwise
the HIV prevalences by age projected by both models
were very similar.
Estimated age-speciﬁc HIV incidence
The estimated age at highest risk of HIV infection
was much older among males (33 years) than females
(25 or 23 years old using models 1 or 2 respectively)
(Fig. 3).
Prevalence by time since infection, time to death
from HIV/AIDS
Since model 2 provided a better ﬁt to the HIV preva-
lence data than model 1, for both males (deviance
of model 1=47.6 on 31 D.F. and model 2=44.9 on 29
D.F.) and females (deviance of model 1=49.8 on 32
D.F. and model 2=32.8 on 30 D.F.), it was used to
estimate the HIV prevalence by time since infection
and time to death and the need for ART.
The proportion of HIV-infected adults who had
been infected for <5 years fell from 100% at the
start of the HIV epidemic to an estimated 46% of
infected males and 40% of infected females by 2005
(Fig. 4, top panels). The model predicted that the
proportion of adults who had been infected between
5 and 9 years peaked at 45% of males in 1998
and 53% of females in 1999, before falling to 32%
of males and 31% of females in 2005. The pro-
portion estimated to have been infected foro10 years
peaked in 2004 for both sexes, at 22% for males
and 30% for females and had not fallen appreciably
by 2005.
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Fig. 1. Top panels : Observed and estimated trend in HIV prevalence (%) among individuals in the community aged o15 years, by sex and year (%). Bottom panels :
Estimated annual HIV incidence in the community among individuals aged o15 years, by sex and year (% per year). Two models were used in which the trend in HIV
incidence was or was not permitted to decrease from its peak. Bars show 95% conﬁdence intervals around data-point estimates.
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Initial ART need
The estimated initial need for ART varied consider-
ably with the assumed period of eligibility. In the
default scenario, assuming that all those within 2
years of death from HIV/AIDS would be eligible for
ART, 2.1% (2.0% of males and 2.2% of females) of
adults aged o15 years in Karonga District were esti-
mated to be in need of ART in 2005 (Fig. 4, bottom
panels). In this scenario, assuming that there were
y119 000 adults in Karonga District this equates to
1206 males and 1324 females in need of ART in
Karonga District in 2005. In the absence of treatment,
the proportion of the population in need of ART
peaked in 2001 at 2.1% of males and 2.5% of females
(Fig. 4, bottom panels). The model suggests that there
is need for ART over a wide age range in both sexes,
peaking among the 35–44 years age group (Fig. 5).
However, if instead we assume that all those
within 1.5 or 2.5 years of death from HIV/AIDS
would be eligible, then 1.6% (1.5% of males and
1.7% of females) or 2.6% (2.5% of males and 2.8%
of females) of adults in Karonga District would be
in need of ART, respectively. The predictions were
less sensitive to the assumption that the period of
eligibility did not vary by age. If we assume that the
eligible period decreased with increasing age at infec-
tion, then the proportion of adults agedo15 years in
need of ART was estimated to be 2.2% (2.1% of
males and 2.3% of females).
Comparison with EPP and Spectrum
Using the standardizedHIV prevalence data for adults
aged 15–44 years a good ﬁt of the HIV prevalence
trend was obtained by the EPP model (not shown).
Based on this HIV prevalence trend, the Spectrum
model predicted theHIV incidence formales agedo15
years peaked around 5.7% per year in 1990 and had
levelled oﬀ around 1.5% per year by 2005. Among
females, the projected HIV incidence peaked around
3.3% per year in 1991 and had levelled oﬀ around
1.7% per year by 2005. In 2005, the initial need for
ART was predicted to be 2.1% (2.0% of males and
2.2% of females) of adults agedo15 years.
DISCUSSION
We estimated the age-speciﬁc HIV incidence trend
and initial need for ART from age-speciﬁc prevalence
trend data. Both our models permitted the HIV
incidence trend to rise and level oﬀ, while the second
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model also allowed the incidence trend to fall from its
peak, if this provided a better ﬁt to the prevalence data.
Both models ﬁtted the overall and age-speciﬁc
prevalence trend well (Fig. 1, top panels and Fig. 2)
and both suggested that current incidence is stable
and similar among men and women (Fig. 1, bottom
panels). The estimated overall and age-speciﬁc pre-
alence trends were similar using the two models
particularly among males, but the historic incidence
trends diﬀered markedly (Fig. 1, bottom panels). The
HIV prevalence data were better ﬁtted by the model
in which HIV incidence fell from its peak. In this
model, the peak HIV incidence was estimated to have
occurred in the early 1990s, over 10 years ago.
A fall in the incidence rate during an epidemic is
expected for the spread of an infectious disease in a
population in which there is heterogeneity in risk
behaviour [21]. HIV spreads more quickly and satu-
rates amongst those at most risk, for example those
with highest rates of partner change. The remaining
susceptibles in the population have lower risk behav-
iour and therefore the average incidence rate may fall.
In addition, the proportion of the population in the
highly infectious primary HIV stage [22] is largest
early in an HIV epidemic. As this proportion falls due
to progression to the less infectious asymptomatic
phase [22], the incidence rate may fall. This will be
countered to some extent later in the epidemic as a
larger proportion of HIV-infected individuals prog-
ress to the more infectious AIDS stage, but this rise
may be partially mitigated by reductions in sexual
activity [22] due to ill health. If secular reductions in
risk behaviour had also occurred in Karonga District,
this incidence decline would have been hastened, but
by itself, this predicted fall in incidence does not imply
reductions in risk behaviour. Corroborating behav-
ioural data are not yet available for this population.
This study suggests there is considerable uncer-
tainty about the initial need for ART due to lack of
deﬁnitive data on the likely period of eligibility [15,
16]. Estimates of the percentage of adults in Karonga
District that were in need of ART ranged between
1.6% and 2.6% if the period of eligibility, prior to the
introduction of treatment, was assumed to be 1.5 or
2.5 years. In contrast, the study suggested that these
predictions for Karonga District were relatively
robust to the assumption that ART eligibility does
not vary by age at infection.
In the default scenario that assumed that the period
of eligibility was 2 years and did not vary by age, the
model predicted that around 2500 (2.1%) adults in
Karonga are currently in need of ART (Fig. 4,
bottom). As around 50 new clients are being enrolled
into ART each month this initial need for ART could
be met within 4 years, but in practice, access and
resource constraints may hinder rollout to those in
need, and the ongoing need for ART is expected to
increase due to reduced rates of HIV/AIDS mortality.
Maintaining availability of ART in the face of
improving survival and the associated increase in the
cumulative pool of eligible individuals will be a major
challenge for ART programmes, unless there is a
concurrent decrease in incidence as a result of behav-
ioural change or reduction in infectivity due to ART.
Predicting the ongoing need for ART is beyond the
current scope of this model but planned studies will
give direct estimates of ART uptake and its impact on
mortality and HIV transmission in Karonga District,
and these data will be used to estimate the ongoing
need for ART in this population.
These predictions suﬀer from the limitations of the
model on which they are based [8]. It was assumed
that the overall risk of HIV infection could vary over
time, but the relative risk of HIV infection by age
did not. This is unlikely to be true over an HIV epi-
demic because HIV initially spreads among higher
risk groups and then among the general population,
and the age distributions of these two groups will
diﬀer. HIV incidence by age was assumed to follow a
Weibull distribution rather than a log-normal distri-
bution [8] and may thus have predicted HIV incidence
rates that were too high in the very young of both
sexes and in older women (Fig. 3). However, despite
these limitations the models provided good ﬁts to the
observed HIV prevalence trend by age (Fig. 2) sug-
gesting that the eﬀect of these model limitations was
not great. The methodology presented here requires
more data than the Williams et al. model [8] but does
allow the HIV incidence trend over time to be pre-
dicted, and age- and sex-speciﬁc HIV incidence and
ART-need to be estimated. An alternative, but prob-
ably equally productive approach would have been to
extend the methods developed by Gregson et al. [23]
that were used to estimate HIV incidence from
HIV prevalence assuming stable endemic conditions.
In the same way, more data would have been required
to parameterize this extended model, but it could
have been used to provide estimates of HIV incidence
and initial ART need over the epidemic and endemic
stages of HIV spread throughout Karonga District.
The standard EPP and Spectrum models, although
based only on overall prevalence data and although
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predicting a shorter, sharper peak for the incidence
curve, gave very similar estimates of initial ART need
to the estimates provided by our model, if we assumed
the same 2-year eligibility period. This supports
the usefulness of EPP and Spectrum for assessing
ART need in other settings with fewer data. However,
our study does highlight the sensitivity of the predic-
tions of both models to the assumed period of ART
eligibility.
This study has presented a simple extension to a
previous method and allows age-speciﬁc prevalence
trend data to be used to estimate the trend in age-
speciﬁc HIV incidence and time since infection. These
predictions can be used for estimating the initial need
for ART.
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